Robin Harper Cowie Sells 24,664 Shares of Biodesix, Inc. (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) CFO Robin Harper Cowie sold 24,664 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $22,690.88. Following the sale, the chief financial officer now directly owns 246,460 shares in the company, valued at $226,743.20. This trade represents a 9.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Biodesix Stock Up 2.4 %

Shares of BDSX opened at $0.96 on Friday. Biodesix, Inc. has a 52-week low of $0.86 and a 52-week high of $2.04. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. The stock has a fifty day simple moving average of $1.24 and a two-hundred day simple moving average of $1.49. The company has a market capitalization of $140.09 million, a PE ratio of -2.47 and a beta of 1.06.

Institutional Investors Weigh In On Biodesix

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC boosted its holdings in Biodesix by 1,140.5% in the 3rd quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after purchasing an additional 21,179 shares during the last quarter. HighTower Advisors LLC raised its position in shares of Biodesix by 17.1% during the 4th quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock valued at $236,000 after buying an additional 22,500 shares during the period. Geode Capital Management LLC raised its position in shares of Biodesix by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock valued at $1,266,000 after buying an additional 22,623 shares during the period. Landscape Capital Management L.L.C. acquired a new position in Biodesix in the third quarter valued at approximately $262,000. Finally, Stephens Inc. AR purchased a new position in Biodesix in the fourth quarter worth approximately $303,000. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.